BioNTech (BNTX) return on equity (ROE)

Return on equity · fiscal 2025
-5.9%

BioNTech (BNTX) earned a return on equity of -5.9% in fiscal 2025 (the year ended December 31, 2025). That is 2.5 percentage points lower than the -3.4% of fiscal 2024. Figures as of 18 Nov 2026, 00:28 UTC, from Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-5.9%
Change on fiscal 2024
−2.5 pts
Highest on record
47.0%fiscal 2022
Lowest on record
-5.9%fiscal 2025
Fiscal years on record
42022–2025

Figures as of . Statements from Yahoo Finance. Figures, not advice.

BioNTech return on equity (ROE), in more detail

Across the 4 fiscal years on record (2022–2025), the highest was 47.0% in fiscal 2022 and the lowest -5.9% in fiscal 2025. The fiscal 2025 figure is no higher than in any of the 3 earlier fiscal years on record, whose median is 4.6%.

History · 4 fiscal years

Return on equity by fiscal year

BioNTech return on equity (ROE), year by year

BioNTech (BNTX) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-5.9% 2.5 pts down
2024-3.4% 8.0 pts down
20234.6% 42.4 pts down
202247.0%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of BioNTech and comparable companies
CompanyReturn on equityFiscal year
Viatris VTRS-23.9%2025
Tenet Healthcare THC33.3%2025
BioNTech BNTX-5.9%2025
Guardant Health GH-302.1%2023
Alnylam Pharmaceuticals ALNY39.8%2025
Zimmer Biomet Holdings ZBH5.6%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BNTX

BioNTech, figure by figure

BioNTech (BNTX) overview: price, valuation and scorecardAll health care companies by market value

BioNTech return on equity (ROE): questions and answers

What is BioNTech's return on equity?

BioNTech (BNTX) earned a return on equity of -5.9% in fiscal 2025 (the year ended December 31, 2025). That is 2.5 percentage points lower than the -3.4% of fiscal 2024.

Is BioNTech's return on equity high or low compared with its own history?

The fiscal 2025 figure is no higher than in any of the 3 earlier fiscal years on record, whose median is 4.6%.

What are the highest and lowest return on equity figures on record for BioNTech?

Across the 4 fiscal years on record (2022–2025), the highest was 47.0% in fiscal 2022 and the lowest -5.9% in fiscal 2025.

How is BioNTech's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “BioNTech (BNTX) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/BNTX/roe

Underlying data: Yahoo Finance.